Fox Run Management, L.L.C. Mirati Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$36.13 - $49.49 $200,196 - $274,224	5,541 Added 49.04%	16,840 $608,000
Q1 2023 May 12, 2023	BUY	$36.54 - $54.26 $412,865 - $613,083	11,299 New	11,299 $420,000
Q3 2022 Nov 07, 2022	BUY	$59.5 - $86.7 $174,751 - $254,637	2,937 Added 80.86%	6,569 $459,000
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $7,127 - $16,145	182 Added 5.28%	3,632 $244,000
Q1 2022 May 10, 2022	BUY	$75.82 - $150.97 $261,578 - $520,846	3,450 New	3,450 $284,000
Q2 2018 Jul 17, 2018	SELL	$26.05 - $52.4 $253,831 - $510,585	-9,744 Closed	0 $0
Q1 2018 Apr 17, 2018	BUY	$17.2 - $34.95 $167,596 - $340,552	9,744 New	9,744 $299,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.